itwire.comAUG 242 min read

Dexcom and Health2Sync partner to advance connected care in Australia and Singapore

Dexcom and Health2Sync have partnered to enhance diabetes care in Australia and Singapore. Health2Sync's platform supports 1.7 million users, while Dexcom provides glucose monitoring tech. The collaboration aims to expand digital health solutions in the Asia-Pacific region.

Original reporting

itwire.com

Published Aug 24, 2026, 1:50 AM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Aug 24, 2026, 2:27 AM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

Dexcom and Health2Sync partner to advance connected care in Australia and Singapore — source image — Source · itwire.com

Decision brief

The 30-second read

Low

Why it matters

The collaboration aims to integrate Dexcom's sensor data with Health2Sync's care platform, potentially improving patient outcomes and expanding Dexcom's ecosystem.

Market read

A strategic partnership that could enhance Dexcom's presence in APAC and signal continued growth in digital health.

What to watch

Regulatory approvals and reimbursement policies in Australia and Singapore could affect rollout speed.

Relevance 5/10Novelty 5/10Timing: announcement today

Background

Dexcom is a leading US CGM provider; Health2Sync operates a digital chronic disease platform in Asia.

Market effects

Sector

Highlights growing demand for digital health solutions in diabetes management.

Regional

May encourage other medtech firms to pursue APAC partnerships.

Global

Supports broader trend of remote patient monitoring adoption.

Counterpoint

What could challenge this read

Partnership may be symbolic with limited short-term revenue impact.

Key entities

Company
Dexcom
US-listed continuous glucose monitoring device manufacturer.
Company
Health2Sync
Asia-Pacific digital health platform for chronic disease management.

Read at source ← All news

SEP 4

$PODDMedAI 8/10

Unpacking Q2 Earnings: Insulet (NASDAQ:PODD) In The Context Of Other Patient Monitoring Stocks

Insulet (PODD) reported Q2 revenue of $801.7M, up 23.5% YoY, beating estimates by 1.9% but missing next quarter's guidance. Peers iRhythm (IRTC), ResMed (RMD), and DexCom (DXCM) also reported earnings, with mixed market reactions. PODD is down 11.6% since reporting, while DXCM is up 20.6%.

finance.yahoo.com3 min

SEP 3

$IRTCMed

Q2 Earnings Highs And Lows: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks

iRhythm (IRTC) reported Q2 revenue of $224.2M, up 20.1% YoY, beating estimates. ResMed (RMD) reported $1.46B in revenue, up 8.6% YoY, in line with expectations. Insulet (PODD) reported $801.7M in revenue, up 23.5% YoY, beating estimates but missing guidance. IRTC stock is down 4.4%, RMD up 3.4%, and PODD down 11.6% since reporting.

finance.yahoo.com2 min

AUG 27

$ABTMedAI 8/10

The FDA Just Gave Abbott a Diabetes First. Is Its Beaten-Down Stock Ready to Wake Up?

Abbott Laboratories (NYSE: ABT) received FDA De Novo authorization for Libre Duo, a wearable that monitors glucose and detects rising ketone levels. The company plans a U.S. launch in 2026. Abbott's stock is down 11.29% over the past year but up 9.2% over the past month. The FDA approval is a regulatory milestone but may not immediately impact revenue.

247wallst.com4 min

AUG 21

$DXCMHighAI 8/10

DexCom stock hits 52-week high at 91.99 USD

DexCom Inc (DXCM) stock reached a 52-week high of $92.01, with a 36% year-to-date return. The company reported Q2 revenue of $1.308B, up 13% YoY, and raised its financial guidance. Analysts increased price targets, with Piper Sandler setting a $95 target. DexCom's inclusion in the FDA's TEMPO program and a perfect Piotroski Score of 9 indicate strong financial health.

investing.com2 min

AUG 21

$DXCMHighAI 9/10

DexCom posts $1.31B quarter as Silvant Capital opens a $5.4M stake

DexCom reported Q2 2026 revenue of $1.31B, up 13.1% YoY, and EPS of $0.70, beating estimates. Silvant Capital bought a $5.4M stake, while insiders sold shares. Analysts maintain 'buy' ratings with targets up to $93. The stock trades near its 12-month high.

app.dealroom.co2 min

AUG 14

$DXCMMed

Is Wall Street Bullish or Bearish on DexCom Stock?

DexCom (DXCM) designs continuous glucose monitoring systems. The stock lagged the S&P 500 and XLV over 52 weeks but gained 37.2% YTD. After Q2 2026 results on Jul. 30, adjusted EPS was $0.70 and revenue $1.31B, up 13% YoY, beating estimates. DexCom raised 2026 revenue guidance to $5.18B-$5.25B. Canaccord lifted its price target to $90; mean target $92.48.

barchart.com4 min